GlassScriptPhysician profile
Henry C Deblasi
NPI 1639179377
$4,219.90
in general payments reported to CMS, 2019-2025
19 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $611 · 2021: $395 · 2022: $626 · 2023: $510 · 2024: $784 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $964.22 | 2019-2025 | Dupixent |
| Optinose US, INC. | $730.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $686.98 | 2021-2025 | Nucala |
| Stryker Corporation | $571.33 | 2019-2022 | |
| Acclarent, INC | $283.86 | 2019-2023 | Relieva Scout, Relieva Spinplus |
| Genzyme Corporation | $170.10 | 2019-2023 | |
| Hikma Pharmaceuticals USA | $167.01 | 2023-2025 | Ryaltris |
| Intersect Ent, INC. | $165.27 | 2020-2021 | |
| Neurent Medical Limited | $116.11 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Phathom Pharmaceuticals, INC. | $84.89 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $61.00 | 2021-2023 | |
| Inspire Medical Systems, INC. | $54.12 | 2023 | Inspire |
| Alk-Abello, INC | $40.75 | 2020-2021 | |
| Integra Lifesciences Corporation | $26.09 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Medtronic, INC. | $25.78 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.21 | 2025 | Tezspire |
| Phadia US INC. | $19.22 | 2025 | Immunocap |
| Smith+Nephew, INC. | $16.70 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Deblasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.